Plain-English translation of NCT07502508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study tests a new medication called icovamenib to see whether adding it to your current Ozempic therapy can help lower your blood sugar more effectively. You would be one of about 60 people with type 2 diabetes who haven't reached their blood sugar goals on Ozempic alone. The study lasts about 12 weeks on the medication, followed by additional follow-up visits over the remaining months.
Many people with type 2 diabetes find that Ozempic alone doesn't bring their blood sugar down enough to reach their target levels. Researchers want to see if this medication could fill that gap and help people achieve better control when used together with their current therapy.
You likely qualify if…
You likely don't qualify if…
You would take either the new medication or a placebo pill by mouth once daily for 12 weeks, in addition to your regular Ozempic injections and any other diabetes medications you're currently on. After the first 12 weeks, you would continue your regular medications and return for follow-up visits and blood tests over the next several months to see how the treatment is working. In total, the study lasts about 56 weeks from start to finish.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States